It inhibits not only MAPK signaling activity but also mutated N‐ and Lysyl‐TRNA Synthetase (KRAS)‐driven signaling, and has shown efficacy in many MAPK‐driven human cancer cell lines and xenograft tumors with KRAS, Neuroblastoma RAS [Ras is a protein coding gene's name], and BRAF oncogenes.181. Here, KRAS is linked to cancer.